Histiocytic sarcoma (HS) is a very rare hematopoietic neoplasm that has been reported in association with other hematological malignancies. Presentation of HS in the central nervous system is even less common. Diagnosis of HS requires the presence of histiocytic markers and the systematic exclusion of markers of other cell lineages. Primary HS central nervous system tumors are aggressive and generally have poor outcomes. There are no standard treatment guidelines due to lack of clinical trials and a limited number of case reports. Here we present a unique case with two primary histiocytic lesions in the brain, refractory to systemic and radiation therapies, that developed after being treated for T-lymphoblastic leukemia 16 years prior. Vital signs were stable; cardiac, abdominal, and respiratory examinations were normal. On neurologic examination, the patient was found to be neglectful of his left side on dual simultaneous stimulation. He was oriented and cranial nerve exam was normal; however, he had mild left hemiparesis and hemiapraxia.
Vital signs were stable; cardiac, abdominal, and respiratory examinations were normal. On neurologic examination, the patient was found to be neglectful of his left side on dual simultaneous stimulation. He was oriented and cranial nerve exam was normal; however, he had mild left hemiparesis and hemiapraxia.
Complete blood count, comprehensive metabolic panel, thyroid stimulating hormone, vitamin B-12 levels, and international normalized ratio were all normal. The CSF was negative for acid fast bacilli (AFB), fungal cultures, and cryptococcal antigen, and CSF cell count analysis showed 3 nucleated cells and 2 red blood cells/µL. White blood cell differential was 8% neutrophils, 12%
lymphocytes, 78% monocytes, and 2% basophils. Glucose was 77 mg/dL, and CSF protein was 25 mg/dL. Positron emission tomography (PET) scan findings were consistent with the MRI and CT scans. There were no hypermetabolic lesions within the remaining visualized portion of the body to suggest a potential source of metastatic disease.
The patient was treated with dexamethasone to decrease the edema and levetiracetam to prevent radiotherapy. An MRI following whole brain radiotherapy, but before focal boost, showed no change in the size of either tumor. Following radiotherapy, the patient was clinically stable initially, but declined to continue treatment. He was enrolled in hospice and died 4 months later, 27 weeks after initial presentation.
Discussion

First described by Mathé et al in 1970,
2 HS is a rare, but aggressive hematopoietic neoplasm.
The World Health Organization currently defines HS as a neoplastic proliferation with morphological and immunophenotypic features of mature tissue histiocytes. 3 Reactive histiocytic infiltrates and other malignancies, particularly B-and T-cell lymphomas, need to be carefully excluded. Prognosis is generally poor due to rapid progression and poor response to therapy.
While HS has been associated with a number of hematological malignancies 4,5 including ALL, 6-15 the risk factors for it are unknown. In some cases, the histiocytic lesions have been shown to share molecular genetic or cytogenetic features with the original leukemia or lymphoma, which may represent transdifferentiation. 13 Feldman et al 4 noted seven cases of HS following follicular lymphoma and found both malignancies to be positive for the t (14;18) translocation in all of the patients, suggesting a common clonal origin. Similarly, Castro et al 13 and Kumar et al 15 described cases in which the leukemic and histiocytic lesions shared identical immunoglobulin B-or T-cell receptor gene rearrangements. Unfortunately, it was not possible to determine if our patient's HS shared any phenotypic or genetic features with the previously diagnosed T-ALL. It is interesting to note that prior to this report, the longest time span reported between ALL and HS was 14 years. 12 Our patient was diagnosed with HS 16 years after T-ALL.
In addition to HS, several other secondary malignancies are associated with ALL, and the 15-year cumulative estimate of secondary malignancies in ALL survivors ranges from 2.5%-4%, reaching approximately 6% at 30 years. 16 The most common secondary malignancies include central nervous system (CNS) tumors, particularly meningiomas and gliomas, but also primitive neuroectodermal tumors and CNS lymphomas, in addition to leukemias/lymphomas, and skin cancers. Many secondary malignancies are thought to be treatment related, especially in the case of CNS tumors and cranial radiation, but chemotherapy may play a role as well. 16 Several histiocytic lesions besides HS are also observed following ALL, including the malignant Langerhans' cell sarcoma. Clinical presentation of HS depends largely on the organ involved, most commonly the intestine, skin, spleen, lymph nodes and bone marrow. 2, 17, 18 Patients may be asymptomatic or may present with a mass and symptoms related to compression of surrounding organs. 19, 20 In our case, the presenting symptoms were related to the brain masses. Although tumors in the CNS are one of the more common secondary malignancies occurring in the context of ALL, lymphoproliferative disorders of the CNS are quite rare. 16 As discussed, the patient did experience CSF involvement and received intrathecal chemotherapy during treatment for T-ALL 16 years prior. In immunocompetent patients, primary CNS lymphomas are quite rare. 21 While MRI and CT imaging studies are useful for visualizing tumors within the CNS, brain biopsy is generally required for definitive diagnosis. In most cases, surgical resection is ruled out due to location of the tumor. Patients are typically treated with irradiation and corticosteroids in addition to intravenous methotrexate and/or leucovorin, 22 although optimal treatment remains unclear. The cytoplasm may contain vacuoles and occasionally has a foamy or xanthomatous appearance. 9 Some tumors may contain a prominent inflammatory infiltrate, hemophagocytosis, and/or increased mitotic activity. 9, 19, 20 While the histological features first described by Mathé et al 2 remain important, greater emphasis is currently placed on immunohistochemical and genetic features for diagnosis. 20 Characteristically, HS tumors express one or more histiocytic markers including CD68, lysozyme, CD163 and CD11c, and do not express B-cell, T-cell, or myeloid doi:10.3121/cmr.2012.1092
Histiocytic sarcoma in brain 16-years post-ALL treatment Page 8 markers. Dendritic cell, epithelial, and melanocytic neoplasms markers should also be excluded. 19, 20 There are no extensive case series of HS in the CNS, but there have been sporadic reports. 1, [24] [25] [26] [27] [28] [29] [30] Most cases of HS in the CNS have been treated with surgery, chemotherapy, and/or radiation therapy; overall, however, prognosis has been poor despite intensive treatment. Based on this and other cases reported in the literature, the median survival for HS in the CNS is 5 months. There is no standard therapy for HS due to the rarity of the disease. Treatment is based on the location and extent of the tumor. Multisystem disease or tumors >3.5 cm carry the worst prognosis. 20 Surgical resection and adjuvant radiation therapy are preferred in localized disease, 19 while combination chemotherapy (i.e. CHOP, ICE, or thalidomide) has been suggested for more aggressive or multifocal presentations. [31] [32] [33] [34] [35] In the present case, combined treatment with methotrexate, temozolomide, and whole brain irradiation with focal boosts to each lesion did not reduce the tumor size, and the patient died 27 weeks after initial presentation.
Conclusion
In summary, we present a unique case with two primary histiocytic lesions in the brain, refractory to systemic and radiation therapies, that developed after being treated for T-ALL 16 years prior. Histiocytic sarcoma is a very rare malignant neoplasm, and presentation in the CNS is even less common. Several reports of HS following hematologic malignancies have been 
